See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Artificial Intelligence
Donald Trump
Social Media
Immigration
Stock Markets
Music
Housing
Nvidia
Natural Disasters
Republican Party
MLB
Inflation
Published • loading... • Updated

Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid

Summary by Hastings Tribune
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 15, 2025-

3 Articles

Hastings TribuneHastings Tribune
Reposted by
Business WireBusiness Wire
Center

Shorla Oncology Announces FDA Orphan Drug Designation for SH-110 to Treat Rare Brain Cancer Using Oral Liquid

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul 15, 2025-

Read Full Article
targetedonc.comtargetedonc.com

FDA Grants Orphan Drug Designation to SH-110, a Liquid Glioma Therapy

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Business Wire broke the news in Crystal River, United States on Tuesday, July 15, 2025.
Sources are mostly out of (0)

Similar News Topics

Cambridge, Massachusetts icon

Cambridge, Massachusetts

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.

News
For You
SearchBlindspotLocal